1 Regulatory History of OTC Phenylpropanolamine Hydrochloride (PPA) Robert L. Sherman Division of OTC Drug Products Center for Drug Evaluation and Research.

Slides:

Advertisements

Similar presentations

Over The Counter Drugs (OTC) Dina R. Utter MSN Student Viterbo University.

Advertisements

PSEUDO- EPHEDRINE VS. EPHEDRINE. If you have been researching weight loss supplements online, you might have encountered the drugs pseudoephedrine and.

WHAT IS MA HUANG?.

Regulatory History of Pediatric Cough/Cold Products Joint Meeting of the Nonprescription Drugs Advisory Committee (NDAC) and the Pediatric Advisory Committee.

Overview of Aspirin and NSAID’s Label Warnings William E. Gilbertson, PharmD. Division OTC Drug Products 1.

NDAC/PADAC Joint Meeting May 11, 2001 Cazemiro R. Martin Regulatory Review Chemist FDA, Division of OTC Drug Products.

Regulatory History and Attributes of Consumer Antiseptics Nonprescription Drugs Advisory Committee Meeting Silver Spring, Maryland October 20, 2005 Colleen.

Development of Guidance Documents Jennifer Scharpf, M. P. H

09-Sep-2003 Predicting human risk with animal research: lessons learned from caffeine/ephedrine combinations Richard J. Briscoe, Ph.D. Safety Pharmacology.

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

Nonprescription Simvastatin in the United Kingdom Michael L. Koenig, Ph.D. Interdisciplinary Scientist Division of Over-the-Counter Drug Products Center.

R A Statistics Group How to Tell the President… Or At Least the Secretary of HHS …The Facts About Ephedra Sally C. Morton, RAND Statistics Group.

Prescription Medications David L. Gee, PhD Professor of Food Science and Nutrition Central Washington University.

Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.

Introduction The purpose of this presentation is to encourage the NDAC to: Endorse (once again) the use of a dosing schedule based on the more finely divided.

1 Scientific Review of Qualified Health Claims (QHC) Barbara O. Schneeman, Ph.D. Office of Nutritional Products, Labeling and Dietary Supplements Center.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.

+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.

Assessing the Impact of a Toll-Free Number for Reporting Side Effects in Direct-to-Consumer Television Ads: Proposed Study Design Kathryn J. Aikin, Ph.D.

NDA/PADAC Joint Meeting Matthew R. Holman, Ph.D. Interdisciplinary Scientist FDA, CDER, Div. Of OTC Drug Products April 22,

1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.

OTC Dermatologic Topical Corticosteroids Michael L. Koenig, Ph.D. Interdisciplinary Scientist Division of Over-the-Counter Drug Products Center for Drug.

Ipecac Syrup: Regulatory History Nonprescription Drugs Advisory Committee Meeting Arlene Solbeck, M.S. Interdisciplinary Scientist, Division of OTC Drug.

Phenylpropanolamine & Risk of Hemorrhagic Stroke Lois La Grenade, M.D., M.P.H. Office of Postmarketing Drug Risk Assessment Center for Drug Evaluation.

Overview of Acetaminophen Label Warnings William E. Gilbertson, PharmD. Division OTC Drug Products 1.

Dietary Supplements Bradford W. Williams Special Assistant Division of Dietary Supplement Programs ONPLDS, CFSAN, FDA.

Luveris ® New Drug Application ( ) Kate Meaker, M.S. Statistical Reviewer Division of Biometrics II Kate Meaker, M.S. Statistical Reviewer Division.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

MCA Risk:benefit analysis of Kava-kava Update as at 12 Feb 2002.

PROPRIETARY NAME EVALUATION AT FDA Jerry Phillips, RPh Associate Director for Medication Error Prevention Office of Drug Safety December 4, 2003.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of.

Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.

FDA’s Draft LDT Framework & Personalized Medicine Update

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

Regulatory History of Sibutramine Eric Colman, MD Division of Metabolism and Endocrinology Products CDER - FDA.

NDAC December 14, Nonprescription Drugs Advisory Committee Meeting Silver Spring, Maryland December 14, 2007 Mary S. Robinson, MS Division of Nonprescription.

OTC NSAIDs AND NEPHROTOXICITY Juan Carlos Pelayo, M. D

ENL1819T Progress Report Confidence in Our Success.

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

Dietary Guidelines for Americans, 2015 & The Nutrition Food Label What’s New? Lacey Chapa Wednesday, June 25, 2014.

Orlistat 60 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees January 23, 2006 Andrea Leonard-Segal, M.D.

Regulatory History of Aspirin Cardiovascular and Renal Drugs Advisory Committee Meeting Michelle M. Jackson, Ph.D. Division of Over-The-Counter Drug Products.

Status of SACHRP Recommendations July 2003-October 2008 Meeting of the Secretary’s Advisory Committee on Human Research Protections October 27, 2008 Michael.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Mevacor 20 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees December 13, 2007 Andrea Leonard-Segal, M.D.

Overview of FDA's Regulatory Framework for PET Drugs

Overview of Gene Therapy Surveillance Inspections Joseph P Salewski, Chief Bioresearch Monitoring Branch CBER.

History of Pediatric Labeling

History and Overview of OTC Topical Antifungal Drug Products Houda Mahayni, R. Ph., Ph.D. Division of Over-the-Counter Drug Products.

1 QTc and Quinolones: recent regulatory actions Joyce Korvick M.D., M.P.H. Office of Drug Evaluation IV Division of Special Pathogens FDA.

Over-the-Counter Drug Products Over-the-Counter (OTC) drug products are those drugs that are available to consumers without a prescription. There.

FDA Regulatory and Compliance Symposium

Monograph Regulation of Weight Control Products for Over-The-Counter (OTC) Use Joint Nonprescription Drugs Advisory Committee and Endocrine and Metabolic.

FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food.

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

OTC NSAID and ASA GI Bleeding Analysis of Spontaneous Reports Nonprescription Drugs Advisory Committee Meeting Joyce P. Weaver, Pharm.D. Office of Drug.

Nonprescription Drugs Advisory Committee Meeting Charles J. Ganley, M.D. Division of OTC Drug Products September 19, 2002.

Nonprescription Drugs Advisory Committee Meeting Charles J. Ganley, M.D. Division of OTC Drug Products September 20, 2002.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

WS-1 Phenylpropanolamine R. William Soller, Ph.D. Senior Vice President and Director of Science & Technology Consumer Healthcare Products Association Washington,

RAPAMUNE ® TM I-1 RAPAMUNE ® WYETH-AYERST RESEARCH January 24, 2002 Subcommittee of the Antiviral Drugs Advisory Committee on Immunosuppressive Drugs January.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

1 INTRODUCTION: Proposed Use of HBOC-201 * in the RESUS (Restore Effective SUrvival in Shock) Trauma Trial Laurence Landow MD, FRCPC Medical Officer, Clinical.

Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.

Department of Health and Human Services1 Update: October 2006 Public Meeting on Emergency Research Diane Maloney, J.D. Associate Director for Policy FDA.

Recent FDA Activities in Safe Use of Opioids Bob Rappaport, M.D. Director, Division of Anesthesia, Analgesia, and Addiction Products Center for Drug Evaluation.

FDA Pathway to Approval: Clinical Requirements for Renal Denervation

ACIP Feb , 2007 Guillain-Barré Syndrome (GBS) Among Recipients of Meningococcal Conjugate Vaccine (MCV4,Menactra®) Update Oct Jan Robert.

Statement on Concerta and Methylphenidate for the June 30, 2005 Pediatric Advisory Committee The FDA has identified two possible safety concerns with.

Presentation transcript:

1 Regulatory History of OTC Phenylpropanolamine Hydrochloride (PPA) Robert L. Sherman Division of OTC Drug Products Center for Drug Evaluation and Research Food and Drug Administration

2 1972: The OTC Drug Review OTC Advisory Review Panels Panels submit reports to FDA Advance Notice of Proposed Rulemaking (ANPR) Public comment and additional data * * * Tentative Final Monograph (Proposed Rule) Public comment and additional data Final Monograph (Final Rule)

3 Classification Categories Category I: Generally Recognized as Safe and Effective Category II: Not Generally Recognized as Safe and Effective Category III: Insufficient Data to Permit Final Classification

4 Marketing Status During OTC Review

5 OTC PPA Rulemakings: 1. Nasal Decongestant Drug Products: Advisory Panel on OTC Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products 2. Weight Control Drug Products Advisory Panel on OTC Miscellaneous Internal Drug Products

6 Status of PPA in the OTC Review

Weight Control ANPR Case reports indicate that PPA doses higher than marketed for weight control cause elevation of blood pressure FDA requests information regarding PPA’s effects on blood pressure and the dissolution rates of timed-release products FDA limits PPA to single doses of mg; 75 mg timed-release, total daily limit: 75 mg

8 Nasal Decongestant Rulemaking PPA deferred from the 1985 proposed rule because of safety issues PPA deferred from the 1994 final monograph Marketing permitted under provisions of the OTC Drug Review

9 1990: FDA’s Conclusions Regarding the Blood Pressure (BP) Studies: PPA causes a biphasic BP response Initially, BP rises above baseline (pressor effect); then falls below baseline (depressor effect) Pressor/depressor effects are dose-related BP effects diminish with repeated dosing Tolerance to the pressor effects develops within a few hours Data inadequate to respond to FDA’s safety concerns

10 House of Representatives Hearing on Dieting, PPA, and Federal Research September 24, 1990 Testimony claiming wide misuse Some witnesses call for removal of PPA FDA receives submissions in rebuttal to Hearing testimony and objecting to data used to support misuse of PPA diet drugs

: Public Meeting on the Safety and Effectiveness of PPA Effectiveness Possible misuse Blood pressure effects Central nervous system adverse events

: FDA’s Conclusion on Effectiveness Based on three 6 to 12-week studies: 75mg controlled-release PPA combined with a reduced-calorie diet is effective for weight control use (up to 3 months) Existing data (reviewed by Panel) are inadequate to support the effectiveness of single doses of 25-50mg PPA for weight control use

: FDA Reviews Spontaneous Reporting System (SRS) Cases spontaneous reports of intracranial bleeding associated with PPA suggest that PPA may increase the risk of hemorrhagic stroke Most reports associated with PPA weight control products and first day of use FDA concludes a case-control study of hemorrhagic stroke would be the most feasible approach to test this hypothesis

14 Difficulties In Assessing PPA Safety: Incomplete, isolated reports of rare events Lack of precise time and dose information Apparent rapid tolerance to the hypertensive effects of PPA Low rate of reported cases associated with widely-used cough-cold products Unknown reporting rate

: Epidemiologist Consultants Review the Stroke Data Interpretation of the data depends critically upon the reporting rate of ADRs (unknown) Available data do not show a causal relationship between PPA and stroke An association between PPA and stroke cannot be ruled out A case-control study is recommended

16 In 1992, FDA Concluded: Although an association between PPA and an increased risk of stroke cannot be ruled out The available data do not warrant removal of PPA from the OTC market while additional data are obtained

17 Yale Hemorrhagic Stroke Project (HSP) Nov 1992: NDMA (now CHPA) proposes study Mar 1993: NDMA submits protocol and voluntary labeling for weight control products Jun 1993: FDA concerns include sample size and exposure window Aug 1993: Comments from Yale investigators Aug 1993: Public Feedback Meeting on protocol Oct 1993: NDMA response to Feedback Meeting Apr 1994: NDMA submits revised final protocol Sep 1994: Case-control study begins

: FDA Proposed Stronger Label Warnings For All OTC PPA Products “Do not use with any allergy, asthma, cough-cold, nasal decongestant, or weight control product containing phenylpropanolamine, phenylephrine, pseudoephedrine, or ephedrine.” “Do not take more than the recommended dose. Taking more can be harmful.” “…Taking more WILL NOT increase weight loss and can be harmful.”

19 October 19, 2000 Agenda: Yale Hemorrhagic Stroke Project (HSP) Consumer Healthcare Products Association (CHPA) FDA’s Office of Postmarketing Drug Risk Assessment (OPDRA) Nonprescription Drugs Advisory Committee (NDAC)